Zacks Research Has Positive Outlook for BMY Q3 Earnings

Key Points

• Zacks Research raised its Q3 EPS forecast for Bristol Myers Squibb to $1.55 from $1.54; the company’s full-year consensus EPS estimate is $6.95.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $66.33. BMY recently traded at $64.08, up 0.7%.
• Bristol Myers Squibb’s latest quarterly results exceeded expectations, with EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion; the company also pays a quarterly dividend of $0.63 per share, yielding about 3.9%.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Zacks Research boosted their Q3 2027 EPS estimates for Bristol Myers Squibb in a report released on Friday, September 11th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $1.55 for the quarter, up from their prior forecast of $1.54. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.95 per share.

A number of other analysts have also commented on the company. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Royal Bank Of Canada upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. Weiss Ratings raised shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. Cantor Fitzgerald reissued a "neutral" rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, BMO Capital Markets restated a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.33.

Bristol Myers Squibb Stock Up 0.7%

NYSE BMY opened at $64.08 on Tuesday. The stock has a market capitalization of $130.90 billion, a P/E ratio of 14.12, a price-to-earnings-growth ratio of 0.30 and a beta of 0.23. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a fifty day moving average of $63.76 and a 200-day moving average of $60.08.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb's revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BMY. Life Cycle Investment Partners Ltd acquired a new position in Bristol Myers Squibb in the 4th quarter valued at $34,406,000. Lazard Asset Management LLC grew its holdings in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock worth $116,693,000 after purchasing an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC increased its position in shares of Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock worth $5,322,000 after purchasing an additional 21,196 shares during the period. Callan Family Office LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at about $3,575,000. Finally, BlackRock Inc. raised its stake in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.